SU1192829A1 - Method of obtaining an agent possessing arrhythmic activity - Google Patents
Method of obtaining an agent possessing arrhythmic activity Download PDFInfo
- Publication number
- SU1192829A1 SU1192829A1 SU843743981A SU3743981A SU1192829A1 SU 1192829 A1 SU1192829 A1 SU 1192829A1 SU 843743981 A SU843743981 A SU 843743981A SU 3743981 A SU3743981 A SU 3743981A SU 1192829 A1 SU1192829 A1 SU 1192829A1
- Authority
- SU
- USSR - Soviet Union
- Prior art keywords
- activity
- alcohol
- obtaining
- solvent
- liosaccus
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
СПОСОБ ПОЛУЧЕНИЯ СРЕДСТВА , ОБЛАДАЮЩЕГО АНТИАРИТМИЧЕСКОЙ АКТИВНОСТЬЮ, включающий экстрагирование сырь спиртом и последующее удаление растворител , отличающийс тем, что, с целью повышени активности целевого продукта, в качестве сырь используют рыбу Liosaccus cutaneus семейства Tetraodontidae, в качестве спирта - метанол , подкисленный уксусной кислотой, а удаление растворител провод т в вакууме.METHOD FOR PRODUCING agents possessing antiarrhythmic activity comprising extracting the feedstock an alcohol and subsequent removal of the solvent, characterized in that, in order to increase the desired activity of the product, as a raw material using fish Liosaccus cutaneus family Tetraodontidae, the alcohol - methanol, acidified with acetic acid, and removal of the solvent is carried out in vacuo.
Description
со юwith y
0000
юYu
со Изобретение относитс к области медицины и может быть использовано с целью получени веществ, обладающих антиаритмической активностью. Целью изобретени вл етс повыщение активности целевого продукта. Пример I. Экстракт из рь1бы Liosaccus cutaneus семейства Tetraodontidae получают следующим образом: гомогенизированную общую ткань Liosaccus; cutaneus (50г) экстрагируют метиловым спиртом, содержащим 5-10% уксусной кислоты по объему. Экстракцию провод т дважды (2Х ЮО мл) при комнатной температуре в течение 10- 15 ч. Объединенные экстракты фильтруют через бумажный фильтр. Фильтрат упаривают в вакууме досуха (при 35-ЗУ С, 10 мм). Остаток раствор ют в 5 мл дистилчировапной воды с образованием прозрачного раствора. Концентраци гипотетического вещества в растворе варьирует от 100 до 300 мг/мл. Пример 2. Защита миокарда от токсического действи ионов кальци в эксперименте достигаетс следующим образом: 0,2 мл полученного экстракта (т.е. ,1 - 3 г/кг) ввод т однократно в хвостовую вену белых беспородных мышей за 1-2 мин до введени хлористого кальци . Остановка сердца осуществл етс введением 3%-ного раствора хлористого кальци в хвостовую вену в дозе 200-300 мг/кг. Без введени экстракта гибель экспериментальных животных наступает в течение нескольких секунд при остановке сердца в систоле в 100% случаев. При введении экс ракта из Liosaccus cutaneus гибель животных происходит лищь в 10-20% случаев. Применение новокаинамида в дозе 40- 60 мг/кг приводит к гибели, 60-80% экспериментальных животных, этмозина в дозе 5-15 мг/кг вызывает гибель 40-60% животных, а изоптина в дозе 1,5-5 мг/кг- 20-40%.The invention relates to the field of medicine and can be used to obtain substances having antiarrhythmic activity. The aim of the invention is to increase the activity of the target product. Example I. An extract from Liosaccus cutaneus of the Tetraodontidae family is prepared as follows: homogenized Liosaccus common tissue; cutaneus (50g) is extracted with methyl alcohol containing 5-10% acetic acid by volume. Extraction is carried out twice (2X10 ml) at room temperature for 10-15 hours. The combined extracts are filtered through a filter paper. The filtrate is evaporated to dryness in vacuo (at 35 ° C, 10 mm). The residue is dissolved in 5 ml of distilled water to form a clear solution. The concentration of the hypothetical substance in the solution varies from 100 to 300 mg / ml. Example 2. Myocardial protection against the toxic effects of calcium ions in the experiment is achieved as follows: 0.2 ml of the obtained extract (i.e., 1-3 g / kg) are injected once into the tail vein of white outbred mice 1-2 minutes before calcium chloride administration. Cardiac arrest is performed by injecting a 3% calcium chloride solution into the tail vein at a dose of 200-300 mg / kg. Without the introduction of the extract, the death of experimental animals occurs within a few seconds when the heart stops in systole in 100% of cases. With the introduction of an extract from Liosaccus cutaneus, the death of animals occurs only in 10-20% of cases. The use of procainamide at a dose of 40-60 mg / kg leads to death, 60-80% of experimental animals, ethmozine at a dose of 5-15 mg / kg causes the death of 40-60% of animals, and isoptin at a dose of 1.5-5 mg / kg - 20-40%.
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SU843743981A SU1192829A1 (en) | 1984-06-06 | 1984-06-06 | Method of obtaining an agent possessing arrhythmic activity |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SU843743981A SU1192829A1 (en) | 1984-06-06 | 1984-06-06 | Method of obtaining an agent possessing arrhythmic activity |
Publications (1)
Publication Number | Publication Date |
---|---|
SU1192829A1 true SU1192829A1 (en) | 1985-11-23 |
Family
ID=21120277
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SU843743981A SU1192829A1 (en) | 1984-06-06 | 1984-06-06 | Method of obtaining an agent possessing arrhythmic activity |
Country Status (1)
Country | Link |
---|---|
SU (1) | SU1192829A1 (en) |
-
1984
- 1984-06-06 SU SU843743981A patent/SU1192829A1/en active
Non-Patent Citations (1)
Title |
---|
Авторское свидетельство СССР № 587939, кл. А 61 К 35/78, 1978. Авторское свидетельство СССР № 613757, кл. А 61 К 35/78, 1978. * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Glinsukon et al. | Acute toxicity of capsaicin in several animal species | |
Parsons | A digitalis-like toxin in the monarch butterfly, Danaus plexippus L | |
Abel et al. | Two crystalline pharmacological agents obtained from the tropical toad Bufo agua | |
DE69317494T2 (en) | Compositions containing mono or polyhydroxylated amino acids for the treatment of insulin independent diabetes mellitus | |
Zehnder et al. | The metabolism of thioridazine (Mellaril®) and one of its pyrrolidine analogues in the rat | |
Rimington et al. | Studies upon the photosensitisation of animals in South Africa X: the icterogenic factor in geeldikkop: isolation of active principles from Lippia rehmanni Pears | |
SU1192829A1 (en) | Method of obtaining an agent possessing arrhythmic activity | |
DE3212882C2 (en) | ||
DE2403122C2 (en) | ||
Gupta et al. | Antiinflammatory activity of some active principles of Lawsonia inermis leaves | |
CN101367799A (en) | Matrine salvianolic acid B double salt and oxymatrine salvianolic acid B double salt, and preparation method and application thereof | |
IE50062B1 (en) | Pharmaceutical compositions containing climbing ivy extracts | |
US4156721A (en) | Method of production of active substance of an antinephrolithiatic, the antinephrolithiatic, and its application for therapy of the nephrolithiasis | |
Hussain et al. | Pharmacological effects of Gardenia erubescens in mice, rats and cats | |
Naude et al. | Studies on South African cardiac glycosides. I. Isolation of toxic principles of Homeria glauca (W. & E.) NE Br. and observations on their chemical and pharmacological properties | |
US3364113A (en) | Senna preparations and methods of making and using them | |
CH661208A5 (en) | MEDICINAL PRODUCT WITH ANTI-ARRHYTHMIC EFFECT. | |
DE2609533C3 (en) | Process for the extraction of active substances, in particular of heteroside esters of caffeic acid, as well as medicaments containing these compounds | |
Chen et al. | The physiological action of the principles isolated from the secretion of the common European toad (Bufo bufo bufo) | |
Tsao et al. | A note on the biological activity of root extracts from Pleiocarpa mutica Benth.(Apocynaceae) | |
DE1804448C3 (en) | β- (2-p-chlorophenyl-thiazol-4-yl) acrylic acid, pharmaceutically acceptable salts thereof and processes for making the compound | |
DE1018874B (en) | Process for the preparation of N-substituted 2-methyl-7-aminoalkoxy-chromones | |
Meijer | The constituents of the bark of diospyros maritima bl. | |
EP0089229B1 (en) | Physiologically active pterocarpan compounds, methods for the isolation thereof and therapeutically active compositions containing them | |
RU2071782C1 (en) | Medicinal preparation "cardiotron" showing antiarrhythmic action |